Market Overview

UPDATE: Allergan Confirms Receipt of Unsolicited Proposal from Valeant, Will Review Offer

Share:
Related AGN
Valeant CEO On Allegations Against The Company And Future M&A Deals
What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts
Sientra: A Breast Implant Pure-Play With A Technologically Superior Implant, Initiating Bullish (Seeking Alpha)
Related VRX
UPDATE: Morgan Stanley Reiterates, Raises Price Target On Valeant Pharmaceuticals As Jublia Formulary Concerns Are Noise
Valeant CEO On Allegations Against The Company And Future M&A Deals
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (“Valeant”) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company (the “Proposal”).

The Allergan Board of Directors, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the Company's stockholders. The Company's stockholders do not need to take any action at this time.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins is serving as legal counsel to the Company.

Posted-In: News M&A Press Releases

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters